Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) EBT (2016 - 2025)

Sunshine Biopharma's EBT history spans 13 years, with the latest figure at $5.5 million for Q4 2025.

  • For Q4 2025, EBT rose 30.16% year-over-year to $5.5 million; the TTM value through Dec 2025 reached $1.3 million, up 11.46%, while the annual FY2025 figure was $1.3 million, 11.46% up from the prior year.
  • EBT reached $5.5 million in Q4 2025 per SBFM's latest filing, up from -$1.0 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $5.5 million in Q4 2025 to a low of -$23.3 million in Q4 2022.
  • Average EBT over 5 years is -$2.0 million, with a median of -$1.1 million recorded in 2023.
  • Peak YoY movement for EBT: plummeted 6461.84% in 2021, then soared 508.23% in 2024.
  • A 5-year view of EBT shows it stood at $667116.0 in 2021, then crashed by 3589.5% to -$23.3 million in 2022, then skyrocketed by 95.58% to -$1.0 million in 2023, then skyrocketed by 508.23% to $4.2 million in 2024, then surged by 30.16% to $5.5 million in 2025.
  • Per Business Quant, the three most recent readings for SBFM's EBT are $5.5 million (Q4 2025), -$1.0 million (Q3 2025), and -$2.0 million (Q2 2025).